SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: The present study aimed to determine whether Gpr55 affects the epilepsy phenotype of F1.Scn1a+/- mice to infer its potential as a new drug target for the treatment of Dravet syndrome.